Federated Hermes
MLYS icon

Federated Hermes’s Mineralys Therapeutics MLYS Stock Holding History

Federated Hermes’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
+6,000
New +$165K ﹤0.01% 1559
2025
Q4 		– Sell
-21
Closed -$796 – 2157
2025
Q3 		$796 Sell
21
-16,507
-100% -$357K ﹤0.01% 2079
2025
Q2 		$224K Buy
16,528
+4,577
+38% +$66.3K ﹤0.01% 1473
2025
Q1 		$190K Sell
11,951
-3,565
-23% -$41K ﹤0.01% 1494
2024
Q4 		$191K Sell
15,516
-1,332
-8% -$17.4K ﹤0.01% 1487
2024
Q3 		$204K Buy
16,848
+4,848
+40% +$58.7K ﹤0.01% 1475
2024
Q2 		$140K Buy
12,000
+6,000
+100% +$75.6K ﹤0.01% 1528
2024
Q1 		$77.5K Sell
6,000
-14,032
-70% -$173K ﹤0.01% 1590
2023
Q4 		$172K Sell
20,032
-2,261
-10% -$17.8K ﹤0.01% 1530
2023
Q3 		$212K Buy
22,293
+1,700
+8% +$22.2K ﹤0.01% 1516
2023
Q2 		$351K Buy
+20,593
New +$308K ﹤0.01% 1465

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes's MLYS Position: Q2 2026 in Review

Federated Hermes opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 6,000 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #1559 among its holdings. This is a return to the name: Federated Hermes previously reported a position in MLYS as recently as Q3 2025.

Federated Hermes first reported a position in MLYS in Q2 2023 and has held it in 11 quarters since. The position peaked at $351K in Q2 2023. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Federated Hermes held 6,000 shares of Mineralys Therapeutics worth $162K as of Q2 2026.
  • Mineralys Therapeutics was a new Federated Hermes position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1559 holding.
  • Federated Hermes first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Federated Hermes's Mineralys Therapeutics position peaked at $351K in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.